Unmet Expectations: miR-34 Plays No Role in p53-Mediated Tumor Suppression In Vivo

Abhinav K. Jain*, Michelle Craig Barton

Program in Genes and Development, Center for Stem Cell and Development Biology, Department of Biochemistry and Molecular Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

In vivo modeling of tumor suppressor p53 functions and regulation has a history of unexpected and even enigmatic outcomes [1], despite the status of p53 as the most frequently mutated gene or dysfunctional pathway in human cancers [2,3]. Beginning with the surprising viability of the first mice deleted for Tp53 [4,5], various hypotheses of compensation, cell type-specificity, stimulus-dependent response, or modifier influences were posed to explain how an exquisitely regulated transcription factor, implicated in a vast array of pathways [6], appeared to have no impact on development. Limited background-specific developmental and fertility problems do occur, especially in female p53-null mice [7,8], and deletion of potentially compensatory p53 family members, p63 and p73 isofoms, leads to profound developmental and tissue-specific phenotypes [9,10]. But overall, the most striking result of p53 loss in vivo is early tumor predisposition in p53−/− mice, which lack genomic surveillance provided by p53-mediated regulation of cell cycle arrest, apoptosis, and senescence.

As reported by Concepcion et al. in this issue of PLoS Genetics [11], expectations built on cell-based studies of p53 response are again unrealized in mouse models. Previously, multiple in vitro analyses suggested that microRNA (miR)-34 family members are important players in a p53-regulated network of genomic surveillance [12–17] (Table 1). Together, these studies strongly supported the view that p53 response to multiple stimuli depended on miR-34, and that ectopic expression of miR-34 was sufficient to elicit p53 response, consistent with miR-34 functioning as a bona fide tumor suppressor. However, Concepcion et al. report that complete inactivation of the entire family of miR-34 genes (miR-34a/b/c) or knockout of each individual miR-34 gene in mice leads to little or no change in p53-mediated functions in tumor suppression [11].

Interest in a miR-34 axis as mediator of p53-response begins with the niche that miRNAs fill in regulation of RNA expression. miRNAs are small, regulatory non-coding RNAs that generally mediate post-transcriptional silencing of a number of specific target mRNAs [18]. More than 50% of human miRNA genes are found within cancer-associated or fragile sites of the genome, which suggests that miRNAs play essential roles in tumorigenesis [19]. The identification of miRNAs as regulatory targets of p53 [20] suggested their potential involvement in tumor suppression, and expanded the repertoire of p53 downstream targets to both coding and non-coding genes. Further, the view that p53 both positively and negatively regulates gene expression could now rely on increased expression of miRNAs as a mechanism for p53-mediated, indirect repression of gene expression [13,20], in addition to the few documented cases of direct repression by p53 binding to chromatin [21–25].

The members of the evolutionarily conserved miR-34 family, which arise from three different transcripts at two different gene loci in vertebrates, were the first of several non-coding RNAs identified as directly activated by p53 in response to genotoxic stress [13,26]. miR-34a is at 1p36, a region commonly deleted in tumors, and miR-34b and miR-34c share a common primary transcript arising from 11q23 [27,28]. miR-34a, b, and c are expressed at very low levels in several types of cancers [28]. Previous reports show that p53 directly activates miR-34a/b/c expression and, dependent on cellular context, they act downstream of p53 in mediating cell cycle arrest or apoptosis [29]. The current list of validated miR-34 downstream targets includes several genes that are repressed during cell cycle arrest or apoptosis when p53 is activated [28].

Given the rationale provided by these studies in cultured cells (Table 1), multiple laboratories created genetic knockout models of either miR-34a or miR-34b/c, or a compound mutant animal harboring homozygous deletion of all three miR-34 family members (miR-34TKO) [11,30]. Surprisingly, mice bearing the miR-34 deletion[s] developed normally, are born at the expected Mendelian ratio, and are fertile [11]. The authors subjected the mice and derived mouse embryonic fibroblasts (MEFs) to a battery of tests to assess any impact on p53-dependent tumor suppression. MEFs obtained from mir-34−/− TKO mice have a slightly higher proliferation rate, but reach senescence with kinetics similar to wild-type MEFs. In response to genotoxic threats, miR-34−/− MEFs are indistinguishable from wild type; they undergo p53-dependent cell cycle arrest and apoptosis. With ectopic expression of oncogenic K-Ras, p53-deficient MEFs are readily transformed, which is not true of K-Ras–expressing miR-34−/− MEFs.

In the intact mouse, the story is similar: aging cohorts of mir-34TKO mice remain healthy with no spontaneous tumors, in contrast to p53-null mice [4]. In fact, miR-34−/− deficient mice remain remarkably healthy and tumor-free for at least 60 weeks after irradiation. Assays of apoptosis in response to irradiation proved positive in tissues of these mice, which additionally exhibited no acceleration of tumor progression in Ep models of B-cell lymphomagenesis. All of these assessments of p53 functions in vivo underline the view that...
miR-34 functions as a tumor suppressor or is an essential component of the p53-tumor suppression network.

Although miR-34 proved nonessential in the most highly studied examples of p53 function (senescence, cell cycle arrest, apoptosis, and tumor suppression), it remains possible that miR-34 is involved in other p53-influenced processes, such as metabolism, autophagy, stem cell quiescence, differentiation, and embryogenesis [6]. For example, specific links between miR-34– and p53-regulated functions have been forged in stem cells [26]. miR-34–deficient MEFs are more efficiently reprogrammed to induced pluripotent stem cells (iPSCs), by expression of pluripotency factors and c-myc [30], compared to wild-type counterparts. While this study of miR-34 as a barrier to reprogramming does not establish a direct tie to p53, it complements multiple reports that depletion of p53 or dysfunctional p53 pathways enhance the efficiency of reprogramming differentiated, somatic cells to iPSCs [31]. Recently, we showed that p53 promotes human embryonic stem cell differentiation by direct activation of p21 and miRNAs, including miR-34a, which repress pluripotency factors and SIRT1 [32]. Taken together, these results indicate that miR-34 has pro-differentiation effects in maintenance of nontransformed, somatic cells, some of which are p53-dependent.

In the future, miR-34–deficient mouse models will be valuable in addressing whether miR-34 functions downstream of p53 in a tissue- and/or context-specific manner. miR-34a, miR-34b, and miR-34c share the same seed sequence and target the same RNAs, although differences in target accessibility or binding affinities may dictate their effectiveness. Genome-wide expression analysis may be needed to determine family member–specific effects, such as the reported regulation of c-MYC by miR-34b/c and not miR-34a [33]. Questions of specificity in gene targets for each member of a miRNA family and potential compensation by other miRNAs may be addressed by studies in these and other miRNA mouse models, perhaps still under development. Non-coding RNAs are thought to act in networks that impact diverse cellular pathways, suggesting considerable challenges ahead in asking the right questions and understanding the functional significance of these RNAs.

### Table 1. A list of different in vitro and in vivo model systems used to study miR-34 functions.

| Model System | Description | miR-34 | Functional Outcome | Ref. |
|--------------|-------------|--------|--------------------|------|
| mESCs        | Mouse embryonic stem cells | Overexpression | Inhibits growth | [12] |
| NSCLCs       | Non-small cell lung cancer cells | Overexpression | G1-arrest | [12] |
| SW480        | p53 mutant colon cancer cells | Depletion | Protection from Staurosporine-induced apoptosis | [12] |
| WI38         | Human diploid fibroblasts | Depletion | Protection from Staurosporine-induced apoptosis | [12] |
| IMR900       | Primary lung fibroblasts | Overexpression | Growth inhibition (G1 and G2 arrest), and senescence | [13] |
| A549         | Human alveolar adenocarcinoma cells | Overexpression | G1-arrest | [13] |
| HCT116       | Human colon cancer cells | Overexpression | G1-arrest | [13] |
| TOV21G       | Human ovarian cancer cells | Overexpression | G1-arrest | [13] |
| MEFs         | Mouse embryonic fibroblasts | Overexpression | Apoptosis | [13] |
| H1299        | Human lung cancer cells | Overexpression | Reduced colony formation | [14] |
| U2OS         | Human osteosarcoma cells | Depletion | Reduction in Etoposide-induced apoptosis | [14] |
| HCT116 (p53<sup>+/−</sup> or p53<sup>−/−</sup>) | Human colon cancer cells | Long-term overexpression | Apoptosis | [15] |
| HCT116, RKO  | Human colon cancer cells | Overexpression | Suppression of proliferation and induction of senescence | [16] |
| Mouse xenograft model | HCT116 or RKO cells were inoculated into nude mice | Subcutaneous administration of miR-34a/atelocollagen complexes | Suppression of cell proliferation and reduction in tumor volume | [16] |
| H1299        | Human lung cancer cells | Overexpression | Apoptosis | [17] |
| U2OS         | Human osteosarcoma cells | Overexpression | G1-arrest and reduction in colony formation | [17] |
| MiaPaCa2, BxPC3 | p53 mutant human pancreatic cancer cell lines | Overexpression | Inhibited clonogenic cell growth and induction of apoptosis and G1 and G2 arrest; sensitized the cells to chemotherapy and radiation | [34] |
| OSN1, OSN2  | Neoplastic epithelial ovarian cells | Overexpression | Suppression of proliferation and reduced colony formation | [35] |
| Kelly, NGP   | Neuroblastoma cells with MYCN amplification (+MNA) | Overexpression | Reduction in proliferation and increased apoptosis | [36] |
| SK-N-A5      | Neuroblastoma cells without MYCN amplification (-MNA) | Overexpression | Reduction in proliferation and increased apoptosis | [36] |
| Mouse mir34a<sup>−/−</sup>; mir34b/c<sup>−/−</sup> | mir34-34 knockout mouse in C57BL/6 background | Germline deletion of mir-34 | Efficient reprogramming, no effect on proliferation | [30] |
| Mouse mir34<sup>−/−</sup> | mir34 knockout mouse in129Sv/Jae and C57BL/6 mixed background | Germline deletion of mir-34 | Normal p53 activity | [11] |

doi:10.1371/journal.pgen.1002859.t001
References

1. Spike BT, Wahl GM (2011) p53, stem cells, and reprogramming: tumor suppression beyond guarding the genome. Genes Cancer 2: 404–419.
2. Soussi T (2007) p53 alterations in human cancer: more questions than answers. Oncogene 26: 2145–2156.
3. Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 mutations in human cancer. Science 253: 49–53.
4. Harvey M, McArthur MJ, Montgomery CA Jr, Butel JS, Bradley A, et al. (1993) Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nat Genet 5: 225–229.
5. Jacks T, Remington L, Williams BO, Schmitt DR, et al. (1999) p63 is a p53 homologue of the E2F pathway in human colon cancer cells. Proc Natl Acad Sci U S A 104: 15472–15477.
6. Vousden KH, Prives C (2009) Blinded by the light: the growing complexity of p53. Cell 137: 413–431.
7. Sah VP, Attardi LD, Mulligan GJ, Williams BO, Bronson RT, et al. (2007) A microRNA component of the p53 network mediates repression of alpha-fetoprotein gene expression by specific DNA binding. Mol Cell 19: 1279–1289.
8. Hu W, Feng Z, Teresky AK, Levine AJ (2007) p53-mediated activation of miR-34a and the induction of p53-dependent apoptosis. Mol Cell 26: 743–752.
9. Vousden KH, Prives C (2009) Blinded by the light: the growing complexity of p53. Cell 137: 413–431.
10. Yang A, Walker N, Bronson R, Kaghad M, Emery EM, Halachmi S, et al. (1994) Tumor spectrum analysis in p53-mutant mice. Curr Biol : CB 4: 1–7.
11. Vouwen KH, Pries C (2009) Blinded by the light: the growing complexity of p53. Cell 137: 413–431.
12. Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Capodieci PL, Oosterwegel M, et al. (2007) p53-mediated repression of miRNA-34a and the induction of p53-dependent apoptosis. Mol Cell 26: 743–752.
13. Chang TC, Wentrel EA, Kent GA, Ramachandran K, Mullendore M, et al. (2007) Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 26: 743–752.
14. Tarasov V, Jung P, Verdoodt B, Lodiglin D, Epanchinteve A, et al. (2007) Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle 6: 1386–1395.
15. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281–297.
16. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, et al. (2004) Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 101: 2999–3004.
17. He L, He X, Lowe SW, Hannon GJ (2007) microRNA join the p53 network—another piece of the puzzle. Nature 447: 1130–1134.
18. Raver-Shapira N, Marziano C, Meiri E, Spector Y, Rosenfeld N, et al. (2007) Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell 26: 731–743.
19. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281–297.
20. He L, He X, Lowe SW, Hannon GJ (2007) p53-mediated transcriptional repression. J Biol Chem 281: 25134–25142.
21. Lee KC, Crowe AJ, Barton MC (1999) p53-mediated repression of alpha-fetoprotein gene expression by specific DNA binding. Mol Cell Biol 19: 1279–1288.
22. Lin CP, Chou YJ, Hsiao GG, He L (2012) The emerging functions of the p53-miRNA network in stem cell biology. Cell Cycle 11: 2063–72.
23. Versteeg R, Caron H, Cheng NC, van der Drift P, Slater R, et al. (1995) Ip36: every subband a suppressor? Eur J Cancer 31A: 538–541.
24. Riley T, Song T, Chen P, Levine A (2008) Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 9: 402–412.
25. Ho J, Benchimol S (2003) Transcriptional repression mediated by the p53 tumour suppressor. Cell Death Differ 10: 401–408.
26. Lin CP, Chou YJ, Hsiao GG, He L (2012) The emerging functions of the p53-miRNA network in stem cell biology. Cell Cycle 11: 2063–72.
27. Versteeg R, Caron H, Cheng NC, van der Drift P, Slater R, et al. (1995) Ip36: every subband a suppressor? Eur J Cancer 31A: 538–541.
28. Hermeking H (2010) The miR-34 family in cancer and apoptosis. Cell Death Differ 17: 193–199.
29. Hermeking H (2007) p53 enters the microRNA world. Cancer Cell 12: 414–418.
30. Chou YJ, Lin CP, Ho JY, He X, Okada N, et al. (2011) miR-34a-miRNAs provide a barrier for somatic cell reprogramming. Nat Cell Biol 13: 1353–1360.
31. Krizhanovsky V, Lowe SW (2009) Stem cells: The promises and perils of p53. Nature 460: 1085–1086.
32. Jain AK, Allon K, Iaconino M, Mahen E, Milezarek RJ, et al. (2012) p53 regulates cell cycle and microRNAs to promote differentiation of human embryonic stem cells. PLoS Biol 10: e1001268. doi:10.1371/journal.pbio.1001268
33. Leucci E, Cocco M, Orsini A, De Falco G, van Cleef P, et al. (2008) MYC translocation-negative classical Burkitt lymphoma cases: an alternative pathogenetic mechanism involving miRNA de-regulation. J Pathol 216: 440–450.
34. Liu Q, Hao X, Zhang M, Tang W, Yang M, et al. (2009) MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS ONE 4: e6016. doi:10.1371/journal.pone.0006016
35. Gamey DC, Fleckner-Nikkin A, Goldsmith AK, Wang W, Nikitin AY (2007) MicroRNA-34a and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res 67: 9433–9439.
36. Welch C, Chen Y, Stallings RL (2007) MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene 26: 5017–5022.